v3.25.4
OTHER EXPENSE, NET
 12 Months Ended
Dec. 31, 2025
Other Income and Expenses [Abstract]  
OTHER EXPENSE, NET OTHER EXPENSE, NET
Other expense, net for the years 2025, 2024 and 2023 consist of:
(in millions)202520242023
Asset impairments$— $5 $— 
Restructuring, integration and separation costs58 26 44 
Gain on sale of assets(6)(5)— 
Litigation and other matters10 5 3 
Acquired in-process research and development costs33 18 — 
Acquisition-related costs7 4 25 
Acquisition-related contingent consideration(27)(9)2 
Other expense, net
$75 $44 $74 
The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with reducing headcount and other cost reduction initiatives. Restructuring, integration and separation costs for the years 2025, 2024 and 2023 were $58 million, $26 million and $44 million, respectively, and primarily consist of employee severance costs. These severance costs were provided under an ongoing benefit arrangement and were therefore recorded once they were both probable and reasonably estimable in accordance with the provisions of ASC 712-10, “Nonretirement Postemployment Benefits”.
Acquired in-process research and development costs in 2025 primarily relates to the acquisition of Whitecap Biosciences, as discussed in Note 4, “ACQUISITIONS AND LICENSING AGREEMENTS”.
Acquisition-related contingent consideration in 2025 primarily reflects changes in: (i) the timing of regulatory approval of certain pipeline products and (ii) the estimated amount and timing of projected cash flows of certain products.